Company Filing History:
1 out of 1,745 
1 out of 157 
1 out of 116 
Years Active: 2024
Title: Romain Solinhac: Innovator in Vascular Health
Introduction
Romain Solinhac is a notable inventor based in Toulouse, France. He has made significant contributions to the field of vascular health, particularly in understanding and addressing ischemic conditions. His work focuses on preserving vascular endothelial cell barrier integrity, which is crucial for patient recovery following ischemic events.
Latest Patents
Romain Solinhac holds a patent for the "Use of PI3KC2B inhibitors for the preservation of vascular endothelial cell barrier integrity." This invention addresses the critical issue of ischemia, a condition characterized by reduced blood flow and oxygen to an organ. The patent highlights the importance of re-establishing blood flow and re-oxygenation after an ischemic episode to limit irreversible damage. However, reperfusion can lead to increased vascular permeability, contributing to edema and tissue damage. Solinhac's research demonstrates that genetic inhibition of PI3K-C2β reduces cerebral infarction in two ischemia/reperfusion models and improves neurological outcomes. This genetic inhibition stabilizes the blood-brain barrier after ischemic stroke and reduces inflammation. The invention provides a method for preserving vascular endothelial cell barrier integrity in patients by administering a therapeutically effective amount of a PI3KC2β inhibitor.
Career Highlights
Throughout his career, Romain Solinhac has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université Paul Sabatier Toulouse III. His research has significantly advanced the understanding of vascular health and the mechanisms involved in ischemic conditions.
Collaborations
Romain has collaborated with notable colleagues, including Marie-Pierre Gratacap and Jean Darcourt. These partnerships have contributed to the depth and impact of his research in the field.
Conclusion
Romain Solinhac's innovative work in vascular health, particularly through his patent on PI3KC2B inhibitors, showcases his commitment to improving patient outcomes in ischemic conditions. His contributions are vital in the ongoing quest to enhance recovery and reduce complications associated with ischemia.